Trilaciclib: Experimental Treatment for Triple-Negative Breast Cancer (TNBC)

Scientific rationale and therapeutic potential

Trilaciclib is a short-acting CDK4/6 inhibitor given as a 30-minute IV infusion prior to chemotherapy. Trilaciclib is designed to:

Preclinical and clinical results (see: Publications)

Trilaciclib has potential in TNBC based on:

G1 is currently recruiting patients for a Phase 2 trial in TNBC

G1T28-04 Study  
  • First/second-line metastatic TNBC
  • Multi-center, randomized, open-label
  • Gemcitabine and carboplatin + trilaciclib
  • Approximately 90 patients
  • Identifier: NCT02978716

For additional information on the trials, please visit:

Click here for printable version of our trilaciclib TNBC clinical trial fact sheet